89Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model

Logan D. Stone1,4, Adriana V. F. Massicano2, Todd M. Stevens3, Jason M. Warram1, Anthony B. Morlandt4, Suzanne E. Lapi2 & Hope M. Amm4,*

Accurate assessment of tumor margins with specific, non-invasive imaging would result in the preservation of healthy tissue and improve long-term local tumor control, thereby reducing the risk of recurrence. Overexpression of epidermal growth factor receptor (EGFR) has been used in other cancers as an imaging biomarker to identify cancerous tissue. We hypothesize that expression of EGFR in ameloblastomas may be used to specifically visualize tumors. The aims of this study are to measure the specificity of radiolabeled 89Zr-panitumumab (an EGFR antibody) in vivo using patient-derived xenograft (PDX) models of ameloblastoma and positron emission tomography/computed tomography (PET/CT) scans. In PDX of ameloblastomas from four patients (AB-36, AB-37, AB-39 AB-53), the biodistribution of 89Zr-panitumumab was measured 120 h post-injection and was reported as the injected dose per gram of tissue (%ID/g; AB-36, 40%; AB-37, 62%; AB-39 18%; AB-53, 65%). The radiolabeled %ID/g was significantly greater in tumors of 89Zr-panitumumab-treated mice that did not receive unlabeled panitumumab as a blocking control for AB-36, AB-37, and AB-53. Radiolabeled anti-EGFR demonstrates specificity for ameloblastoma PDX tumor xenografts, we believe 89Zr-panitumumab is an attractive target for pre-surgical imaging of ameloblastomas. With this technology, we could more accurately assess tumor margins for the surgical removal of ameloblastomas.

Ameloblastomas (AB) are odontogenic tumors that display locally aggressive and destructive behavior. They are most likely to occur in the posterior mandible during the fourth or fifth decade of life1–3. While these tumors are benign, they can grow to large sizes and cause extensive damage to the bone and surrounding tissue. They are epithelial tumors believed to be derived from the epithelial rests formed during dental development. Conservative treatments have shown to have a recurrence rate of approximately 30%, due to incomplete resection of tumors. There currently is no biomarker used or diagnostic strategies beyond biopsy. This makes surgical determination of accurate resection margins difficult, thus leading to the high recurrence rate2. New strategies for targeted imaging should be developed to improve accurate assessment of tumor margins. As a potential biomarker, the majority of ameloblastomas have been shown to be epidermal growth factor receptor (EGFR) positive3,8–13. One study that examined 193 cases of AB found that 85–100% of these cases were positive expression of EGFR3. This expression has been previously targeted in our lab14. Using EGFR as a biomarker for ameloblastoma would allow for the differentiation of tumor compared to normal tissue. Past experiments have used Food and Drug Administration approved antineoplastic antibodies that can be modified for use in fluorescence-guided surgery, including the anti-EGFR drugs cetuximab and panitumumab14,15. These FDA approved drugs are able to target the EGFR in cancer and have been approved for treatment in head and neck cancers and colorectal cancer using cetuximab and panitumumab, respectively16.

Here we use panitumumab radiolabeled with the radioisotope zirconium-89 (89Zr), which has been proven to be stable in vitro and in vivo17. This radioactive isotope allows for immunoPOSITRON emission tomography18 imaging of the tumor, in particular as the longer half-life of 89Zr (compared to other radioactive isotopes) is compatible with the biodistribution and half-life of the antibody19. The use of 89Zr-panitumumab for PET-CT is
a non-invasive method to monitor EGFR expression providing a useful way to identify EGFR-expressing tumors. Radiolabeled panitumumab has been studied for head and neck cancers and metastatic colon cancer as a means to determine lymph node involvement and tumor margins prior to an invasive surgery3,17,19,20, (NCT03764137). This strategy could provide better assessment of ameloblastoma tumor margins prior to surgery and reduce the invasive impact and outcomes for the patient.

Results
Preparation and characterization of $^{89}$Zr-panitumumab. Panitumumab was conjugated to 10 M fold of DFO-Bz-NCS and showed high radiochemical yield (> 95%) when labeled with $^{89}$Zr in all labeling conditions studied. Challenging the final product by adding DTPA into the solution did not affect the yield, confirming the high conjugation and labeling efficiency (results not shown). EGFR-positive SCC-1-luc+ cells were used to determine the $^{89}$Zr-panitumumab specific binding and immunoreactivity. Over 30% of the total $^{89}$Zr-panitumumab added was bound to the cells (32.75% ± 2.00%; Fig. 1), and this high binding was blocked when non-radio labeled panitumumab was present (0.80% ± 0.03%, Fig. 1). The immunoreactivity $^{89}$Zr-panitumumab was over 85% (87.26% ± 15.98%) and thus panitumumab was not affected by the conjugation with 10 M fold of DFO-Bz-NCS or the radiolabeling process.

Evaluation of EGFR expression using $^{89}$Zr-panitumumab and PET-CT images. Mice implanted with tumor samples from 4 separate ameloblastoma patients were injected with $^{89}$Zr-panitumumab with or without unlabeled panitumumab as a blocking control. During the experimental optimization a study was performed with biodistribution 5 days post-injection, however, the high background caused by the high blood pool compromised the imaging quality and consequent tumor visualization. The imaging quality was greatly improved by allowing the antibody to clear 2 more days from the body with imaging 7 days post-injection.

Tumor uptake (%ID/g; percentage injected dose per gram of organ or tissue) in AB-36, AB-37 and AB-53 groups, but not the AB-39, was significantly higher in the non-blocking group compared to the blocking group, indicating the presence of EGFR expression in those tissues (Fig. 2A and B). However, the SUV mean (standard uptake value) for the AB-39 group was significantly higher for non-blocking group when compared to the blocking group (Fig. 2C). The SUV mean was also significantly higher in the non-blocking group for AB-37 and AB-53, corresponding with the significant tumor uptake (%ID/g). PET/CT images acquired showing ameloblastoma localization, as well as the difference between non-blocking and blocking groups, can be visualized in Fig. 3.

Ex vivo histopathological confirmation of AB. In order to confirm the presence of tumor in the PDX models, the implanted tissue was stained with hematoxylin and eosin (H&E). Microscopic examination demonstrated the presence of solid type ameloblastoma for each tumor specimen (Fig. 4). Immunohistochemistry also confirmed EGFR expression in the same areas confirmed by pathologist to be tumor (Fig. 4).

Discussion
In the present study, we have confirmed that $^{89}$Zr-panitumumab has shown specificity for EGFR by binding to control EGFR-expressing cells, SCC-1-luc+ (Fig. 1)14. This binding can be blocked by the addition of unlabeled panitumumab. Previously, $^{89}$Zr-panitumumab, produced in the same manner, has shown specificity for EGFR expressed in A431 epidermoid carcinoma cells and HCT116 colon cancer cells in vitro and in vivo17. The specificity of $^{89}$Zr-panitumumab for EGFR has been demonstrated in multiple EGFR+ cell lines and allows us to target EGFR in ameloblastomas17,21,22. Our group has previously shown that ameloblastoma cells expresses EGFR at a similar level to SCC cells14. We previously targeted EGFR in ameloblastomas using fluorescently labeled cetuximab, another EGFR antibody, which showed specificity for ameloblastoma in vitro and in vivo15. While targeted fluorescence imaging is attractive due to being non-invasive and having low toxicity, it is unknown if near infrared fluorescence imaging is feasible within bone23. Ameloblastoma occurs within in the bones of the jaw, primarily in the mandible12. Imaging tumors within bone remains challenging with no consensus regarding the optimal imaging strategies. In

![Figure 1. Cellular uptake of $^{89}$Zr-panitumumab in EGFR expressing SCC cells. Percent of administered activity detected in SCC-1-luc+ with and without blocking with unlabeled EGFR antibodies (***p < 0.0001).](https://doi.org/10.1038/s41598-022-23531-z)
head and neck squamous cell carcinoma (HNSCC) patients with mandibular tumor involvement, CT, magnetic resonance imaging (MRI), ¹⁸F-fluorodeoxyglucose (FDG)-PET, SPECT/CT, and PET imaging have all been evaluated, and each approach has advantages and disadvantages. Radiolabeled EGFR antibodies have shown promise in imaging tumors where fluorescent imaging may not be feasible. Zirconium-89 is a positron emitter with a relatively long half-life (3.3 days). Previous pharmacokinetic studies have demonstrated that it takes 5–7 days to obtain optimal tumor-to-non-tumor ratios for antibody localization in vivo, making zirconium-89 compatible with panitumumab as a PET agent. Small animal PET with radiolabeled antibodies, such as with ⁸⁹Zr-panitumumab, provide the benefit of specificity for tumor tissue. When combined with the high sensitivity of PET, this technique allows for imaging of the tumor area and margins. The current imaging modalities

Figure 2. Detection of ⁸⁹Zr-panitumumab in ameloblastoma patient derived xenograft models. Ameloblastoma tumor tissue from four patients was implanted in mice (AB-36, AB-37, AB-39, AB-53). All mice received ⁸⁹Zr-panitumumab and were imaged at 7 days post injection. In the blocking group, 1 mg of unlabeled panitumumab was given 120 min prior to ⁸⁹Zr-panitumumab. (A) Systemic biodistribution of ⁸⁹Zr-panitumumab in non-blocking vs blocking groups. %ID/g = % injected dose per gram. (B) Average tumor uptake of ⁸⁹Zr-panitumumab. (C) Standardized uptake value (SUV) in each tumor group. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars indicate standard error.
Figure 3. In vivo PET/CT imaging of ameloblastoma tumors. Representative MicroPET/CT images were obtained 7 days post injection. All animals received $^{89}$Zr-panitumumab. The blocking group (+ block) also received an unlabeled dose of panitumumab. Tumors were implanted in the flanks of mice. Maximum intensity is demonstrated in the upper panels, and the axial slice at the center of the tumor is shown in the bottom panels (as indicated by arrow). The scale, expressed as standardized uptake value (SUV), is at the far right.
Figure 4. Ameloblastoma tumor tissue was confirmed in xenografts after resection by pathologic assessment (NB = non-blocking group; B = blocking group). Resected tumors, 7–9 weeks post implantation, were processed, embedded in paraffin and stained with hematoxylin and eosin (H&E, first column) or anti-EGFR for immunohistochemistry (second column) (20×). Negative controls (third column) show staining without primary antibody.
used for ameloblastoma include radiography, CT, and MRI. In some cases, contrast-enhanced MRI, cone beam CT (CBCT), or FDG-PET may be used. However, the former modalities lack specificity for tumor tissue, and solid ameloblastomas only demonstrate mild or moderate FDG uptake. This is likely due to the low proliferative state and glucose use of these tumors. The ability to specifically and visibly label tumor cells with precision, regardless of their proliferative state, would be beneficial for patients facing extensive surgeries. \(^{89}\)Zr-panitumumab provides specificity to EGFR-expressing tumors, like ameloblastomas, and the ability to visualize tumors prior to surgery.

In the current study, we show \(^{89}\)Zr-panitumumab localized to ameloblastoma tumors using PET/CT scans (Fig. 2). This demonstrates \(^{89}\)Zr-panitumumab can bind to ameloblastoma PDX tissue in vivo similar to localization shown in previous models with cetuximab-IRDye800. Biodistribution and SUV data showed significant localization to in vivo ameloblastoma tissue compared to other organs and sites within the mouse (Fig. 2). Differences in \(^{89}\)Zr-panitumumab uptake occurred in the tumor tissue between the blocking and non-blocking groups demonstrating the specificity for EGFR. The PET images demonstrate that \(^{89}\)Zr-panitumumab can be used to identify the tumor tissue from four distinct patients with ameloblastoma in vivo using the mouse PDX model (Fig. 3). Ex vivo the presence of ameloblastoma tumor and expression of EGFR was confirmed in each AB PDX (Fig. 4). These findings establish that \(^{89}\)Zr-panitumumab is tumor-specific and highly sensitive to detecting ameloblastoma tumors in vitro.

Currently it is difficult for surgeons to evaluate these ameloblastoma tumors radiographically. In general, 30% of head and neck tumors resections were found to have positive margins during pathology review. Ameloblastoma margins are often assessed by qualitative visual inspection or based on radiographs of the resected specimen. Frozen section histology has also been used to evaluate the soft tissue adjacent to intrabony tumors to assess margin status; however, the assessment of bony resection margins requires decalcification and sectioning, which requires at least a one-day precluding frozen section analysis on bone margins. Margins of 1–2 cm are currently considered adequate for curative resection. However, a 1 cm margin beyond the radiographically-visible disease has been associated with a 29% recurrence rate. Because of this, over-aggressive resection with wide margins up to 3 cm for ameloblastoma has been advocated to avoid recurrence. However, the over-resection of healthy tissues results in unnecessary facial deformity, malocclusion, neurosensory disturbances, and speech and swallowing dysfunction. In many cases, radical resection requires extensive reconstruction, including microvascular composite free tissue transfer. The management of recurrences following reconstruction may require the sacrifice of a bone graft or soft tissue constructs. This leads to additional reconstructive procedures and donor site morbidity. The ability to accurately assess tumor margins using targeted imaging could help to preserve healthy tissue and improve long-term local tumor control. Here we provide proof-of-principle data that ameloblastoma tumors can be specifically visualized in vivo and \(^{89}\)Zr-panitumumab may provide precise preoperative imaging of tumor margins.

The principal limitations of this study include limited sample size and subcutaneous implantation of the primary tumor xenografts. Although the number of ameloblastoma patients recruited to this study was limited, we were able to detect significant localization of \(^{89}\)Zr-panitumumab to ameloblastoma tumors in vivo, which would aid surgeons in planning successful resections. For this preclinical study, the ameloblastoma xenografts were implanted in the flanks of mice. Although subcutaneous xenografts, including the PDX models used here, provide a useful model of the disease and proof-of-principle data, these models do not replicate the tumor environment. Ameloblastomas occur within an intrasosseous environment, primarily the mandible. Studies in HNSCC have shown the benefits of using PET/CT in visualizing the bone involvement and tumor extension into bone. Studies used \(^{18}\)F-FDG or \(^{18}\)F-NaF PET/CT to accurately access the mandibular extension of HNSCC. This approach allows for the benefits of tumor labeling provided by PET imaging and higher anatomical resolution provide by CT. However, these PET modalities lack specificity as they are based on the metabolic capacity of the tissue or bone. Our approach utilizes an immuno-PET agent, \(^{89}\)Zr-panitumumab, which binds to EGFR expressed by the ameloblastoma tissue. The first human clinical trials using \(^{89}\)Zr-panitumumab for imaging showed that it has clinical application to cancers that overexpress EGFR and can be safely used in humans. Other papers have demonstrated that \(^{89}\)Zr labeled antibodies have a wide range of clinical applications that need to be further explored to efficiently use it in a clinical setting. Our study demonstrates that \(^{89}\)Zr-panitumumab is taken up by AB xenografts. This suggests that further studies should be done to examine the efficiency in the mandible of humans.

Conclusion

In conclusion, our data have shown that radiolabeled anti-EGFR antibody, \(^{89}\)Zr-panitumumab, can be used to effectively identify ameloblastoma tumor tissue in vivo. This was demonstrated through significant localization of \(^{89}\)Zr-panitumumab to ameloblastoma PDX tissue as measured by biodistribution and SUV. This approach takes advantage of the EGFR expression seen in ameloblastoma tumors, while providing feasibility of utilizing advanced imaging for ameloblastoma detection. We believe the technologies we have described, once translated into the clinical setting, will allow surgeons to more confidently excise ameloblastomas by accurately assessing the tumor location and preserving normal tissue, thereby improving long-term local tumor control and, ultimately, patient outcomes.

Materials and methods

Tumor specimens and preparation. Tissue samples were collected from consented patients with a diagnosis of ameloblastoma, who underwent surgical resection at the University of Alabama at Birmingham (UAB) between 2018 and 2020. During the study period, patients were identified with a diagnosis of primary or recur-
rent ameloblastoma requiring a microvascular free flap. Patients included in this study had solid ameloblastoma with mandibular bone involvement with negative lymph nodes.

The UAB Institutional Review Board independently reviewed and approved the present study, and all patients provided written informed consent. The ablative surgeon (A.B.M.) obtained the tumor tissue for the study distant from the specimen edges using a method that did not interfere with the pathologist's ability to assess the surgical margins. To confirm the presence of the tumor before implantation, a portion of the tissue was analyzed by a board-certified pathologist (T.M.S.) using standard frozen section techniques and the World Health Organization diagnostic criteria for AB. All patients enrolled in the study had a solid/multicystic ameloblastoma of the mandible. AB-37, AB-39, and AB-53 were the follicular histopathological subtype; AB-36 was a desmoplastic subtype. Once the tumor presence had been confirmed, the explants were dissected into 2 × 2-mm pieces, rinsed in Dulbecco's modified Eagle medium (DMEM)/F-12 supplemented with penicillin/streptomycin and amphotericin (ThermoFisher, Waltham, MA). The remainder of the surgical specimens were processed by the pathology department in accordance with the standard of care for surgical pathologic specimens.

**Antibodies and reagents.** The production of [89Zr]oxalate was carried out the University of Alabama at Birmingham, Cyclotron Facility using Y sputtered solid targets as described previously. Panitumumab ( Vectibix®) was purchased from Amgen ( Thousand Oaks, CA). Desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) was purchased from Macrocyclics ( Dallas, TX). Dimethyl sulfoxide (DMSO) and sodium carbonate were purchased from Sigma-Aldrich (St. Louis, MO). HEPES was purchased from ACROS Organic (Fair Lawn, NJ). All other chemicals were purchased from Fisher Scientific (Hampton, NH) unless stated otherwise.

**Cell culture.** Squamous cell carcinoma-1 luciferase-positive (SCC-1-luc+) EGFR-positive cells were kindly donated by Dr. Jason Warram, PhD and cultivated in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (FBS) and supplemented with 50 µg/mL gentamycin in a humidified incubator with 5% CO₂ at 37 °C. All other reagents for cell culture were purchased from Fisher Scientific (Hampton, NH).

**Preparation of 89Zr-panitumumab.** Conjugation of DFO-Bz-NCS to panitumumab and radiolabeling with [89Zr]oxalate were performed following previous methods. Briefly, tenfold molar excess of DFO-Bz-NCS dissolved in DMSO was incubated with panitumumab in 0.1 M sodium carbonate buffer (pH 9) at 37 °C for 1 h. After conjugation, the DFO was removed by Zeba spin desalting columns using 1 M HEPES buffer pH 7.1–7.3 via Zeba spin desalting columns (40 kDa Molecular Weight Cut-Off, Thermo Scientific, Rockford, IL). The purified DFO-panitumumab was labeled with protein concentration was quantified using a bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, IL). The purified DFO-panitumumab was labeled with radioiodination of 89Zr-oxalate using desalting columns under the following conditions: 12.5 µg of mAb and 50 µCi of 89Zr (12.5 µg/50 µCi); 62.5 µg/50 µCi; 5 µg/50 µCi and 2.5 µg/50 µCi (0.148, 0.296, 0.370 and 0.740 MBq per µg mAb respectively) in a final volume of 50 µL at 37 °C for 1 h.

The radiochemical yield was determined by instant thin-layer chromatography (iTLC) using 50 mM DTPA as the mobile phase. The labeled antibody with radiochemical yields ≥ 95% chromatography was used for in vitro and in vivo studies without further purification. When needed (RCY < 95%), the labeled antibody was purified using Zeba spin desalting columns.

**Immunoreactivity and specific cell binding in vitro.** The specific binding of 89Zr-panitumumab was assessed in SCC-1-luc+ cells in vitro. The immunoreactivity and specificity was previously shown by Chang et al. Cells (2.5 × 10⁴) were seeded in a 12-well plate and incubated in a humidified incubator with 5% CO₂ at 37 °C for 48 h. Half of the wells received 25 ng of 89Zr-panitumumab in 1 mL of culture medium (total binding) and half received the same solution plus 25 µg/mL panitumumab in 1 mL of culture medium (competitive/blocking binding). The cells were incubated for 1.5 h at 37 °C; 5% CO₂. The percentage of 89Zr-panitumumab bound to the cells in presence or absence of competitor was calculated.

**Animal model PDX.** Athymic mice (Envigo, East Millstone, NJ) aged 3–6 weeks, were obtained and housed in accordance with the UAB Animal Resource Program guidelines, after approval by the Institutional Animal Care and Use Committee. The mice were anesthetized with isoflurane and incision sites were prepared with 3M Durprep, iodine Povacrylex (Fisher Scientific) and ethanol. Prior to surgery, the mice were treated with carprofen. An incision was made between the skin and muscle of the left flank, followed by developing a subcutaneous pocket at this site. A tumor piece (2 × 2 mm) was placed in the pocket and the wound was closed with staples (Fine Science Tools, Foster City, CA). The tumors were allowed to establish for 4–6 weeks after PDX implantaition. Number of mice per group varied based on patient tissue availability (n = 5 in all groups except AB-39 blocking where n = 4).

**Evaluation of EGFR expression using PET/CT images.** For each PDX model, mice were divided into 2 groups of 5 mice (except where noted). The blocking group received 3.7 MBq (100 µCi) 5 µg of antibody of 89Zr-panitumumab via tail vein, and the blocking group received 1 mg of unlabeled panitumumab 120 min prior to receiving the same radioactive dose of 89Zr-panitumumab. Static PET images were acquired 7 days post injection for 20 min using GNEXT PET/CT (SOFIE, Dulles, VA). The images were reconstructed using a MLEM 3D protocol and the standard uptake value (SUV) of each tumor was calculated using VivoQuant software (Invi- cro, Boston, MA). After image acquisition, mice were euthanized, the main organs were harvested, weighed,
and counted in a gamma counter to calculate the percentage of injected dose in each organ. All the tumors were paraffin embedded and used for pathologic analysis.

**Immunohistochemistry.** Formalin-fixed, paraffin-embedded (FFPE) tumors were cut (5 mm sections), deparaffinized, and rehydrated. The sections were placed in citrate antigen retrieval buffer (R&D Systems, Minneapolis, MN) for 20 min at 97 °C and blocked in 3% hydrogen peroxide for 10 min. The samples were incubated with EGFR antibody (A10, Santa Cruz, 1:50) overnight at 4 °C. Horseradish peroxidase polymer-conjugated antibody was applied for 10 min and detected using diaminobenzidine tetrachloride with hematoxylin counterstain (Invitrogen, Waltham, MA). The negative control was processed with secondary antibody and without primary antibody.

**Statistical analysis.** Statistical analysis was performed using Student’s t-test (p < 0.05) for single comparison. All analyses were performed on GraphPad Prism V9 (GraphPad Software Inc, La Jolla, CA).

Received: 20 February 2022; Accepted: 1 November 2022
Published online: 10 November 2022

**References**

1. Ladeinde, A. L. et al. Odontogenic tumors: A review of 319 cases in a Nigerian teaching hospital. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. **99**(2), 191–195 (2005).
2. Johnson, N. R. et al. A prospective epidemiological study for odontogenic and non-odontogenic lesions of the maxilla and mandible in Queensland. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. **115**(4), 515–522 (2013).
3. Amm, H. M. & MacDougall, M. Molecular signaling in Benign odontogenic neoplasia pathogenesis. *Curr. Oral Health Rep.* **3**(2), 82–92 (2016).
4. Laborde, A. et al. Ameoblastoma of the jaws: Management and recurrence rate. *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* **134**(1), 7–11 (2017).
5. Hong, J. et al. Long-term follow up on recurrence of 305 ameloblastoma cases. *Int. J. Oral Maxillofac. Surg.* **36**(4), 283–288 (2007).
6. Almeida, R. et al. Recurrence rate following treatment for primary multicystic ameloblastoma: Systematic review and meta-analysis. *Int. J. Oral Maxillofac. Surg.* **45**(3), 357–369 (2016).
7. Sachs, S. A. Surgical excision with peripheral ostectomy: A definitive, yet conservative, approach to the surgical management of ameloblastoma. *J. Oral Maxillofac. Surg.* **64**(3), 476–483 (2006).
8. Vered, M., Shohat, I. & Buchner, A. Epidermal growth factor receptor expression in ameloblastoma. *Oral Oncol.* **39**(2), 138–143 (2003).
9. Goncalves, C. K. et al. Immunohistochemical expression of p63, epidermal growth factor receptor (EGFR) and notch-1 in radicular cysts, dentigerous cysts and keratocystic odontogenic tumors. *Braz. Dent. J.* **23**(4), 337–343 (2012).
10. Ikawa, M. et al. Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas. *J. Oral Pathol. Med.* **42**(5), 424–434 (2013).
11. Kuppy, K. J. et al. High frequency of BRAF V600E mutations in ameloblastoma. *J. Pathol.* **232**(5), 492–498 (2014).
12. Abdel-Aziz, A. & Amin, M. M. EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: Possible role in local recurrence. *Dian. Pathol.* **7**, 12 (2012).
13. Siweira, A. S. et al. Matrix metalloproteinases, TIMPs and growth factors regulating ameloblastoma behaviour. *Histopathology* **57**(1), 128–137 (2010).
14. Morlandt, A. B. et al. Fluorescently labeled cetuximab-IRDye800 for guided surgical excision of ameloblastoma: A proof of principle study. *J. Oral Maxillofac. Surg.* **78**(10), 1736–1747 (2020).
15. Negenthal, E. L. et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. *Clin. Cancer Res.* **21**(16), 3658–3666 (2015).
16. Giusti, R. M. et al. FDA drug approval summary: Panitumumab (Vectibix). *Oncologist* **15**(5), 577–583 (2007).
17. Chang, A. J., De Silva, R. A. & Lapi, S. E. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. *Mol. Imaging* **12**(1), 17–27 (2013).
18. Binfield, P. In At PLoS ONE we’re batty about bats, in PLoS: Public Library of Science. 2008. p. Web log message.
19. Lindenberg, L. et al. Dosimetry and first human experience with (89)Zr-panitumumab. *Am. J. Nucl. Med. Mol. Imaging* **7**(4), 195–203 (2017).
20. Nayak, T. K. et al. PET and MRI of metastatic peritonal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. *J. Nucl. Med.* **53**(1), 113–120 (2012).
21. Bhattacharyya, S. et al. Zirconium-89 labeled panitumumab: A potential immuno-PET probe for HER1-expressing carcinomas. *Nucl. Med. Biol.* **40**(4), 451–457 (2013).
22. Bhattacharyya, S. et al. Synthesis and biological evaluation of panitumumab-IRDye800 conjugate as a fluorescence imaging probe for EGFR-expressing cancers. *Med. Chem. Commun.* **3**(9), 1337–1346 (2014).
23. Warram, J. M. et al. Antibody-based imaging strategies for cancer. *Cancer Metastasis Rev.* **33**(2–3), 809–822 (2014).
24. Seeburg, D. P., Baer, A. H. & Aygun, N. Imaging of patients with head and neck cancer: From staging to surveillance. *Oral Maxillofac. Surg. Clin. N. Am.* **30**(4), 421–433 (2018).
25. Kolk, A. et al. Combined SPECT/CT improves detection of initial bone invasion and determination of resection margins in squamous cell carcinoma of the head and neck compared to conventional imaging modalities. *Eur. J. Nucl. Med. Mol. Imaging* **41**(7), 1363–1374 (2014).
26. Benedetto, R. et al. (89)Zr-DFO-cetuximab as a molecular imaging agent to identify cetuximab resistance in head and neck squamous cell carcinoma. *Cancer Ther.* **13**(7), 1432–1442 (2014).
27. Gamoh, S. et al. The role of computed tomography and magnetic resonance imaging in diagnosing clear cell ameloblastoma: A case report. *Oral Maxillofac. Surg. Clin. N. Am.* **(4), 7257–7261 (2017).
28. Konouchi, H. et al. Usefulness of contrast enhanced-MRI in the diagnosis of unicystic ameloblastoma. *Oral Oncol.* **42**(5), 481–486 (2006).
29. Li, D. et al. 3D cone beam computed tomography reconstruction images in diagnosis of ameloblastomas of lower jaw: A case report and mini review. *J. Xray Sci. Technol.* **26**(1), 133–140 (2018).
30. Seno, S. et al. FDG-PET findings of ameloblastoma: A case report. *Springerplus* **4**, 250 (2015).
31. Niu, N. et al. Multiple organ metastases from ameloblastoma detected by FDG PET/CT imaging. *Clin. Nucl. Med.* **38**(12), 1009–1011 (2013).
32. Fernandes, G. S. et al. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation. *BMC Cancer* **18**(1), 887 (2018).
33. Day, K. E. et al. Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma. *Laryngoscope* **123**(11), 2681–2689 (2013).
34. Daramola, J. O., Ajagbe, H. A. & Oluwasanmi, J. O. Recurrent ameloblastoma of the jaws—a review of 22 cases. *Plast. Reconstr. Surg.* **65**(5), 577–579 (1980).
35. Carlson, E. R. & Marx, R. E. The ameloblastoma: Primary, curative surgical management. *J. Oral Maxillofac. Surg.* **64**(3), 484–494 (2006).
36. Lopez, R. et al. Prospective comparison of (18)F-NaF PET/CT versus (18)F-FDG PET/CT imaging in mandibular extension of head and neck squamous cell carcinoma with dedicated analysis software and validation with surgical specimen. A preliminary study. *J. Craniomaxillofac. Surg.* **45**(9), 1486–1492 (2017).
37. Lopez, R. et al. Value of PET/CT 3D visualization of head and neck squamous cell carcinoma extended to mandible. *J. Craniomaxillofac. Surg.* **46**(5), 745–748 (2018).
38. Stalder, S. A. et al. Value of SUVmax for the prediction of bone invasion in oral squamous cell carcinoma. *Biology* **9**(2), 23–33 (2020).
39. Lubeck, J. E. & Magliocca, K. R. Evaluation of the bone margin in oral squamous cell carcinoma. *Oral Maxillofac. Surg. Clin. N. Am.* **29**(3), 281–292 (2017).
40. Stalder, S. A. et al. Value of SUV/Vmax for the prediction of bone invasion in oral squamous cell carcinoma. *Biol. (Basel)* **9**, 2 (2020).
41. McKnight, B. N. & Viola-Villegas, N. T. (89)Zr-ImmunopET companion diagnostics and their impact in clinical drug development. *J. Label. Comp. Radiopharm.* **61**(9), 727–738 (2018).
42. Sivapathasundaram, B., Biswas, P. G. & Preethi, S. The World Health Organization classification of odontogenic and maxillofacial bone tumors: An appraisal. *J. Oral Maxillofac. Pathol.* **23**(2), 178–186 (2019).
43. Querrin, S. L. et al. Production of Zr-89 using sputtered yttrium coin targets (89)Zr using sputtered yttrium coin targets. *Nucl. Med. Biol.* **50**, 11–16 (2017).
44. Warram, J. M. et al. Fluorescence imaging to localize head and neck squamous cell carcinoma for enhanced pathological assessment. *J. Pathol. Clin. Res.* **2**(2), 104–112 (2016).
45. Massicano, A. V. F. et al. Imaging of HER2 with [(89)Zr]pertuzumab in response to T-DM1 therapy. *Cancer Biother. Radiopharm.* **34**(4), 209–217 (2019).
46. McGregor, P. K., et al. In *Design of Playback Experiments—The Thornbird Hall Noto ARW CONSENSUS*. Playback and Studies of Animals Communication, ed. P. K. McGregor. vol. 228, 1–9 (Plenum Press Div Plenum Publishing Corp., 1992).

**Acknowledgements**

The authors thank Henry Kendrick, Andrew Zhang, and Joshua Holsey for experimental assistance.

**Author contributions**

A.V.F.M., J.W.M., A.B.M., S.E.L., and H.M.A. contributed to study concepts and design. T.M.S. and A.B.M. performed the clinical studies. L.D.S., A.V.F.M., and H.M.A. performed the experimental studies and data analyses. L.D.S., A.V.F.M., and H.M.A. performed the statistical analyses. L.D.A., A.V.F.M., and H.M.A. prepared the manuscript. A.V.F.M., T.M.S., J.M.W., A.B.M., S.E.L., and H.M.A. edited the manuscript.

**Funding**

This study represents independent research supported by National Institutes of Health (NIH) and Oral Maxillofacial Surgery Foundation. This work was supported by the National Institute of Dental and Craniofacial Research [NIDCR, K99/R00-DE023826, R21-DE029603] and an Oral Maxillofacial Surgery Foundation [Research Support Grant 2015] and 1R37CA245157. Imaging provided by the UAB Small Animal Imaging Facility and supported by the National Cancer Institute [NCI, P30CA013148] and the O’Neal Comprehensive Cancer Center.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to H.M.A.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022